Nitric oxide, a product of nitric oxide synthase activity, relaxes vascular smooth muscle and elevates brain blood flow. We evaluated the importance of eNOS to cerebral blood flow augmentation after L-arginine infusion and in creases in flow after eNOS upregulation in SV -129 mice. Blood flow was measured by laser-Doppler flowmetry before and after L-arginine infusion (450 mg/kg during a 15-minute pe riod) or measured by 14C-iodoamphetamine indicator fraction ation or 14C-iodoantipyrine tissue equilibration techniques. rCBF increased by 26% (laser Doppler flowmetry) after L arginine infusion but did not change in mutant mice deficient in eNOS expression. After eNOS upregulation by chronic sim vastatin treatment (2 mg/kg subcutaneously, daily for 14 days),
L-arginine amplified and sustained the hyperemia (38%) and increased absolute brain blood flow from 86 ± 7 to 119 ± 10 mLiIOO g per minute. Furthermore, pretreatment with simvas tatin enhanced blood flow within ischemic brain tissue after middle cerebral artery occlusion. Together, these findings sug gest that eNOS activity is critical for blood flow augmentation during acute L-arginine infusion, and chronic eNOS upregula tion combined with L-arginine administration provides a novel strategy to elevate cerebral blood flow in the normal and isch emic brain. Key Words: HMG-CoA reductase inhibitor Type III nitric oxide synthase-Nitric oxide-Endothelium Hyperemia.
cortex (Dalkara et ai., 1994) and reduces the size of experimental brain infarction in rats (Morikawa et ai., 1994) and may therefore be useful therapeutically. How ever, alternative mechanisms have been put forth to ex plain the putative linkage between L-arginine adminis tration and vasodilation because under a wide range of physiological conditions, the enzyme eNOS is apparently saturated with substrate in vitro (Morikawa et ai., 1994; Harrison, 1997; McDonald et ai., 1997; Michel and Feron, 1997) .
We recently reported that chronic simvastatin (HMG CoA reductase inhibitor) treatment upregulates ca1cium dependent NOS activity within endothelial cells, en hances basal brain blood flow levels, and reduces experi mental brain infarct size in wild-type mice (Endres et ai., 1998) . However, mice deficient in eNOS gene expres sion (eNOS-null mice) are refractory to simvastatin treat ment (Endres et ai., 1998) . In this report, we extend evidence implicating NO and its derivatives as mediators of blood flow augmentation after L-arginine and chronic statin administration. We examined whether L-arginine' infusion increases flow in genetically-engineered mice deficient in type III NOS (endothelial NOS), and whether increasing NOS protein by chronic statin treatment aug ments the blood flow response to infused L-arginine dur ing basal conditions and during cerebral ischemia.
METHODS

Drugs
HMG-CoA reductase inhibitor (simvastatin) was purchased from commercially-available sources, purified, isolated, and the activity was verified in vitro. It was chemically activated by alkaline hydrolysis before injection (Endres et aI., 1998; Laufs et al. 1997 ). L-arginine hydrochloride (Sigma, St. Louis, MO, U.S.A.) was dissolved in distilled water and adjusted to pH 7.0 with sodium hydroxide.
General preparation
All experiments were conducted in accordance with National Institutes of Health and Massachusetts General Hospital (MGH) Institutional guidelines. 129/SVEvTacBR mice (male) were purchased from Taconic Farms (Germantown, NY, U.S.A.). Type III NOS mutant mice lacking the eNOS gene were generated at MGH with a mixed background (129/SV and C57BU6 mice) (Huang et aI., 1995) . Animals were allowed free access to food and water ad libitum. Anesthesia was in duced with 2% to 2.5% halothane and maintained with 1.0% halothane in 70% N20 and 30% 02' Mice were intubated transorally, placed in the stereotaxic frame, and ventilated ar tificially (SAR-830/P, CWE, Ardmore, PA, U.S.A.). End-tidal CO2 was monitored by a microcapnometer (Columbus Instru ments, Columbus, OH, U.S.A.). The femoral artery and vein were cannulated with a polyethylene catheter (PE-IO, Intra medic, Becton Dickinson, Sparks, MD, U.S.A.) for continuous arterial blood pressure and heart rate monitoring and for drug infusion. In L-arginine infusion studies, urethane (750 mg/kg intraperitoneally) was administered and halothane was with drawn gradually after completing surgery and before L arginine. An additional dose of urethane (500 mg/kg intraper itoneal) was added 30 minutes later. Mice were immobilized with pancuronium bromide (0.4 mg/kg intraperitoneal). There was no blood pressure or pulse elevation in response to tail pinch during anesthesia. Arterial blood gas and pH were ana lyzed at baseline and after drug infusion in each experiment. Rectal temperature was maintained at approximately 37°C with a thermostatically controlled mat (temperature control, FHC, Brunswick, ME, U.S.A.).
Protocol for laser-Doppler flowmetry
The skull was exposed by a longitudinal skin incision and regional cerebral blood flow (rCBF) was monitored over the intact skull by laser-Doppler nowmetry (BPM 403A, Vasamed ics, MN, U.S.A.) using a needle probe (0.8 mm in diameter, p-433) placed over the left parietal cortex. Animals were in jected subcutaneously (abdomen) with simvastatin (2 or 20 mg/kg) daily for 2 or more weeks before experimentation. Anesthetized animals were instrumented as described previ ously. After achieving stable baseline rCBF (5 to 10 minutes), L-arginine (450 mg/kg) or saline vehicle was infused via the left femoral vein at a constant rate of 100 [LUkg per minute for 15 minutes. rCBF was recorded for an additional 40 minutes whereas depth of anesthesia was kept constant. 
Measurement of plasma level of amino acids
To determine whether plasma arginine levels differed after amino acid infusion in the presence or ab�ence of simvastatin, blood was sampled before (n = 3 per group) or 40 minutes after L-arginine infusion (n = 4 per group). Plasma was pre pared from citrated blood (3.82% adjusted 0.1 vol/vol sodium citratc) and stored at -80°C after centrifugation. Amino acid analysis was carried out by ion-exchange chromatography us ing a Beckman 6300 amino acid analyzer (Palo Alto, CA, U.S.A.). Samples were deproteinized and half-diluted with 3% sulfosalicylic acid in lithium buffer containing 5% per milli gram internal standard (S-2 aminoethyl-L-cysteine).
Absolute cerebral blood flow measurement after L-arginine
The protocol of anesthesia and infusion of L-arginine was the same as described previously. In addition, the jugular vein was cannulated. Thirty minutes after start of infusion of L-arginine or saline, CBF was determined using an indicator fractionation technique described previously ( Fujii et aI., 1997) . Arterial blood was withdrawn continuously from the femoral artery at a rate of 0.3 mUmin with a pump (Stoelting, Wood Dale, IL, U.S.A.). One microcurie of N-isopropyl-[methyl 1,3_14C]_p_ iodoamphetamine (American Radiolabeled Chemicals Inc., St. Louis, MO, U.S.A.) dissolved in 0.1 mL saline was injected into the jugular vein as a bolus (<I second). Twenty seconds after injection, the animal was decapitated and the blood with drawal terminated simultaneously. The brain was removed quickly and frozen in isopentane chilled with dry ice. After adding Scintigest (Fisher Scientific, Fair Lawn, NJ, U.S.A.) and incubating (50°C overnight), scintillation fluid and H202 were added. Twelve hours after shaking, radioactivity in brain and blood were measured by liquid scintillation spectrometry (RackBeta 1209, Pharmacia-Wallac, Gaithersburg, MD, U.S.A.). CBF was calculated according to the method of Van Uitert and Levy (1978) and Betz and Iannotti (1983) .
Absolute CBF measurement after middle cerebral artery occlusion and statin pretreatment
To determine the impact of chronic simvastatin treatment on blood flow after permanent middle cerebral artery (MCA) oc clusion, male and female SV-129 mice (20 to 25 g) were killed at 4 hours after occlusion for absolute CBF measurement. These mice had been treated with simvastatin (2 mg/kg per day, subcutaneously) or an equivalent amount of vehicle (phosphate buffered saline) for 14 days before the onset of ischemia.
Focal cerebral ischemia was induced by occlusion of MCA using the intraluminal filament technique as described before (ZeaLonga et aI., 1989; Huang et aI., 1994) . Briefly, through a ventral midline incision, the left common and external carotid arteries were isolated and ligated. A microvascular clip (Zen temporary clip, Ohwa Tsusho, Tokyo, Japan) was temporarily placed on the internal carotid artery and the pterygopalatine artery. An 8-0 nylon monofilament (Ethicon, Somerville, NJ, U.S.A.) coated with silicone was introduced into the internal carotid artery via the external carotid artery and advanced 10 mm distal to the carotid bifurcation to occlude the MCA.
Regional cerebral blood now was measured using the 14C_ iodoantipyrine technique described previously in mice (Jay et aI., 1988) with some modifications. Briefly, halothane anesthetized mice were infused with 14C-iodoantipyrine (5 [LCi in 100 [LL saline) through the left femoral vein during a I-minute period via a pump, during which time arterial blood samples were collected every 5 seconds (total 50 to 100 [LL) onto preweighed filter paper disks. Animals were then decapi tated immediately. The whole head was immersed at once in eNOS, L-ARGININE, STA TINS, AND CBF 7// isopentane chilled with dry ice (-4SOC) and then stored on dry ice. Radioactivity in blood samples was measured by liquid scintillation spectrometry (RackBeta 1209, LKB) 24 hours later.
The frozen brains were cut into coronal sections of 20 fLm thickness using a cryostat-microtome. The sections were thaw mounted on glass coverslips, immediately dried on a hot plate (60°C ), and exposed to Kodak SB-5 autoradiographic film for 3 days in an X-ray cassette along with a set of calibrated 14C_ polymer standards from Amersham (Arlington Heights, IL, U.S.A.). Coronal sections and regions of interest (ROIs) were selected as described by Hakim et al. (1992) , four sections (I, 2, 3, and 4) corresponding to + 1.54, +0.14, -1.94, and -3.88 mm from bregma, respectively. In each section, the density of the autoradiograms covering 4 to 5 brain structures in both hemisphere was measured with a computerized image analyzer (Imaging Research Inc., St. Catherines, Canada). The software converted the optical density to radioactive content and to CBF using the radioactive standards and the 14C-iodoantipyrine blood curve.
Semiquantitative reverse transcription polymerase chain reaction
Aortas were quickly isolated and frozen after sacrifice. Total mRNA isolation, reverse transcription, and semiquantitative competitive polymerase chain reaction (PCR) were performed according to standard techniques as previously described (En dres et aI., 1998). The sense (5'-TTCCGGCTGCCACCT GATCCTAA-3') and antisense (5'-AACATATGTCCTTGCT CAAGGCA-3') primers for eNOS amplified a 340-bp frag ment of murine eNOS that was confirmed by DNA sequencing. Equal amounts of eNOS and glyceraldehyde-3-phosphate de hydrogenase (GAPDH) reverse transcription-PCR products were loaded on agarose gels. Optical densities of ethidium bromide-stained DNA bands were quantified by an image ana lyzer.
Statistical analysis
Data are presented as mean ± standard error of the mean (SEM). Differences were compared by unpaired two-tailed Stu dent's I-test, by ANOVA preceding Scheffe test (physiologic parameters), by Fisher's protected least-squares difference test (laser Doppler study), or by Student's t-test (absolute CBF measurement). The software StatView 4.0 (Abacus Concepts, Inc., Berkeley, CA, U.S.A.) was used for statistical analysis. P values of <0.05 were considered statistically significant. Tables 1 through 3 . There were no group differences in mean arterial blood pressure and heart rate, although values were elevated in eNOS-null mice, as reported previously (Huang et aI., 1995) . Because blood pressure and heart rate values ob tained for every 5-minute epoch during L-arginine infu sion were not different by more than 10% of baseline values, only baseline values for each group are given in Table 1 . pH values were decreased after L-arginine, con sistent with administering the amino acid at pH 7.0.
RESULTS
Physiologic variables are shown in
reBF response to L-arginine First, we tried L-arginine 300 mg/kg intravenously be cause this dose was shown to enhance reBF in the rat (laser Doppler flowmetry). Only a modest (10%) reBF elevation was detected (n = 4, data not shown). At a greater dose of amino acid (450 mg/kg intravenously), reBF increased after 5 to 10 minutes, but was statisti cally significant after 10 to 15 minutes ( Fig. 1 ). Maxi mum increases reached 26% at 20 to 25 minutes, after Values are mean ± SEM. MABP, mean arterial blood pressure; sim, simvastatin; L-arg, L-arginine.
* p < (J.05 versus L-arginine-infused eNOS null mice; t p < 0.05 versus simvastatin (2 mg/kg) treated L-arginine-infused eNOS null mice; :j: P < 0.05 versus baseline by one-way ANOV A followed by Scheffe test. which blood flow declined to control levels. In eNOS null mice, rCBF did not increase during the 40 minutes after L-arginine infusion; values ranged from -4 to +5% of baseline. In a single experiment, L-arginine (450 mg/ kg) increased CBF by 20% during infusion in a C57BLl6 mouse.
As in the rat, L-arginine infusion (450 mg/kg)in mice did not decrease systemic arterial blood pressure in con trast to modest blood pressure decreases or arterial dila tion in humans (Giugliano et aI., 1997; Nakaki et aI., 1990; Smulders et aI., 1997; Bode-BUger et aI., 1998 ). An increased cardiac output (not determined) may com pensate for vasodilation in animals, although no signifi cant increase in heart rate was observed. Decreases in arterial pH after L-arginine (Reutens et aI., 1997) did not change CBF because Paco2 values did not change (Harper and Bell, 1963) . rCBF response to L-arginine plus simvastatin pretreatment After chronic daily simvastatin (2 and 20 mg/kg), L arginine infusion increased rCBF (laser Doppler flow metry) significantly at the 10 to 15-and 15 to 20-minute epochs during infusion (Fig. 2) . Maximum increases of 29% and 31 % were measured in groups treated with 2 mg/kg and 20 mg/kg simvastatin, respectively. Increased flow was sustained for at least 20 minutes more than for the response to L-arginine without simvastatin treatment. The maximum increase after acute L-arginine plus chronic simvastatin treatment (31 %), however, was not statistically different than for L-arginine alone (26%, Fig.  1 ). In eNOS-null mice, L-arginine infusion did not in-crease rCBF significantly after chronic simvastatin treat ment (2 mg/kg).
We also detected eNOS expression by semiquantita tive reverse-transcription PCR and found that chronic daily simvastatin treatment increased eNOS mRNA lev els dose-dependently in the aorta of wild-type mice (Fig.  3) . No eNOS expression was detected in aortas of eNOS null mice.
Plasma arginine levels
Plasma L-arginine levels (/-Lmol/L) were 45 ± 6 and 40 ± 7 (n = 3 per group) before infusion. Levels increased to 196 ± 12 and 188 ± 18 (n = 4 per group) 40 minutes after beginning L-arginine infusion in groups treated with or without simvastatin, respectively.
Effects of chronic simvastatin treatment plus acute L-arginine infusion on absolute cerebral blood flow
Chronic simvastatin treatment (2 mg/kg) increased, but not significantly, absolute CBF detected by the io doamphetamine method by 14% compared with saline infused, vehicle-treated animals (P > 0.05). However, acute L-arginine infusion (450 mg/kg intravenously) in creased absolute blood flow by 38% in simvastatin treated mice compared with saline-infused, vehicle treated group (P < 0.05) ( Table 2) .
Effects of chronic simvastatin treatment on residual absolute rCBF after middle cerebral artery occlusion
Because simvastatin upregulates eNOS activity, aug ments rCBF, and reduces infarct size (Endres et al. 1998 ), we determined whether simvastatin (2 mg/kg) Artificially ventilated mice were anesthetized with halothane and subjected to permanent MCA occlusion. Arterial blood samples were taken 5 min before and IS min after ischemia. Vaues are mean ± SEM, n = 6 per group. augmented regional blood flow in the MCA territory after acute occlusion. Absolute rCBF values were sig nificantly greater than in vehicle-treated animals in nearly all examined brain regions within the ischemic territory using J4 C-iodoantipyrine autoradiography (Figs. 4 and 5) . This increase was robust in the caudate and putamen. rCBF values ;l1so were greater within homolo gous regions in the non ischemic side. The use of halo thane instead of urethane contributed to the greater flow values in normal brain when the tracer iodoantipyrine was administered.
DISCUSSION
We demonstrate that L-arginine infusion elevates blood flow via eNOS-dependent activity within vascular endothelium. The lack of response in eNOS-null mice is consistent with this conclusion and with previous results showing that topical L-NAME, an inhibitor of NO syn thase, attenuates L-arginine-induced dilation of rat pial vessels (Morikawa et aI., 1994) . The blood flow response to L-arginine following chronic simvastatin treatment further support an association between eNOS activity and rCBF augmentation, and together with results after D-arginine infusion (Morikawa et aI., 1994; Dalkara et aI., 1994) , render unlikely explanations based on flow dependent osmotic mechanisms during amino acid infu sion. We suggest that both the actions of statins and the effects of L-arginine are mediated in part by NO dependent actions on the brain microcirculation, and pos- Fig. 1) . rCBF values for 2 mg/kg-treated animals infused with saline are represented by white (n = 3), L-arginine infusion in 2 mg/kg (n = 5) and 20 mg/kg (n = 6) treated mice are shown as light and dark shades, and 2 mg/kg-treated eNOS-null mice are shown as black bars (n = 2). There was no response to L-arginine in eNOS null mice, whereas the response to L-arginine was robust and prolonged in mice treated with 2 mg/kg or 20 mg/kg simvastatin.
Error bars denote SEM. *P < 0.05 compared with saline infused simvastatin (2 mg) treated mice; tP < 0.05 compared with base line.
sibly by NO-mediated anti platelet and anti-white cell re sponses during acute ischemia (Niu et aI., 1994) . We previously showed that statins elevate eNOS ex pression and significantly increase eNOS activity within mouse blood vessels (unpublished observations, Endres et aI., 1998; Laufs et aI., 1997; Laufs et aI., 1998; . The mechanism relates in part to in creased mRNA stability and eNOS mRNA translation without affecting nNOS or iNOS gene expression. Stat ins cause eNOS-dependent cerebral blood flow increases under basal conditions (Endres et al., 1998 ) and CBF appears to increase further after infusing the eNOS sub strate L-arginine. Blood flow was initially assessed using laser Doppler flowmetry as this technique records rela tive flow changes in real time. Using this technique, we observed that L-arginine enhanced blood flow maximally by 26%, and by 31 % in control and simvastatin-treated animals, respectively, and that the L-arginine response sustained after statin pretreatment. When absolute blood flow was measured using an indicator fractionation tech nique, blood flow increased by 38% after combined sim vastatin pretreatment plus L-arginine versus saline con trol, thereby confirming the advantages of providing ex ogenous substrate after eNOS upregulation. Moreover, the L-arginine effect lasted longer after statin treatment, despite equivalent plasma amino acid levels. Further more, after MCA occlusion, the blood flow in both isch emic and nonischemic brain was significantly greater than in untreated animals, and probably contributed to the infarct sparing effect consistently observed in this paradigm (Endres, et al., 1998) .
The results in eNOS-null mice indicate that the L arginine response is dependent on eNOS expression, al though the mechanism(s) by which L-arginine increases cerebral blood flow is not well-understood. L-arginine may elevate the production of NO by increased substrate availability, However, levels within plasma and cells are substantially greater than the eNOS Km for L-arginine (Arnal et al., 1995; Harrison, 1997; McDonald et al., 1997; Michel and Feron, 1997) . The observation that L-arginine drives NO production even when intracellular L-arginine levels are in excess is termed the "arginine J Cereb Blood Flow Metah. Vol. 20, No. 4. 2000 paradox" (Arnal et al., 1995; Harrison, 1997; McDonald et al., 1997; Michel and Feron, 1997) . Arnal et al. (1995) found that L-arginine reverses L-glutamine's ability to inhibit NO release in bovine aortic endothelial cells and in rabbit aortic rings. In their study, L-arginine dose dependently enhances endothelium-dependent vascular relaxation only when L-glutamine is present, suggesting a complex interplay between L-glutamine and receptor mediated activation of NO synthase. The paradox may be influenced by endogenous NO synthase antagonists such as asymmetrical dimethylarginine (Harrison, 1997) or modified by the L-arginine transporter (CA T1) and eNOS at the caveolae in endothelial cells (McDonald et al., 1997; Michel and Feron, 1997) . The latter mecha nism may facilitate transcellular delivery of substrate to membrane-bound eNOS. The arginine paradox would be unexpected, however, in neurons, axons and synapses where cytosolic nNOS does not reside within membrane bound organelles or, to our knowledge, associate with amino acid transporters. Consistent with this notion, L-arginine infusion does not augment blood flow-associ ated functional activation in human brain (Reutens et al., 1997) , (which in animals is mediated in part by NO release from neurons Ma et al., 1996 », although it does elevate basal cerebral blood flow. Contributions from other mechanisms such as L arginine-induced insulin release (insulin promotes NO dependent vasodilation) cannot be entirely excluded but is unlikely since D-arginine, which can also stimulate insulin release, has no effect on CBF (Giugliano et al., 1997; Steinberg et aI., 1994; Kurz and Harrison, 1997) . Nevertheless, our findings indicate that up-or down regulation of eNOS protein critically modulates the blood flow response to infused L-arginine. The effects of L-argmme administration on human vascular beds have been studied also. Intravenous infu sion of large doses in awake humans (30 g, approxi mately 385 mg/kg during a 30 minute period) modestly decreased blood pressure (4%) and total peripheral re sistance (10%) but not at doses greater than 6 g (Bode Bilger et aI., 1998) . In these studies, urinary nitrate ex cretion and to a lesser extent cyclic guanosine mono phosphate (GMP) increased after L-arginine. The authors found that vasodilator response to L-arginine closely cor responded to its plasma concentration and its effects on endogenous NO production. L-arginine decreased periph eral arterial resistance, increased platelet intracellular cy clic GMP levels, and decreased platelet aggregation (Bode- Bilger et aI., 1994) . In hypercholesterolemic sub jects, L-arginine, but not D-arginine, improved endothe lium-dependent relaxation after methacholine chloride (Creager et ai., 1992) . In another study, L-arginine infu sion augmented nutritive capillary muscular blood flow in patients with peripheral vascular disease (Schellong et aI., 1997) , consistent with impaired NO synthesis in these patients (Bilger et aI., 1997) . The generation of NO may also mediate the increase in absolute blood flow in the brain after L-arginine infusion (Reutens et aI., 1997) , suggesting that augmenting eNOS may improve the ce rebral microcirculation occurring with conditions of vas cular compromise in humans.
Consistent with these findings, L-arginine infusion im-proves rCBF (as detected by laser Doppler flowmetry) within the ischemic penumbra or perinfarct zone and reduces infarct volume in normotensive and hypertensive rats after middle cerebral artery occlusion (Morikawa et aI., 1994) . Only modest flow elevations (from 20% to 30% of basal values) improve electrophysiologic activity within ischemic cortex (Dalkara et aI., 1994) , and eleva tions of this magnitude can be achieved within the isch emic penumbra or perinfarct zone, as evidenced after chronic eNOS upregulation. L-arginine is reportedly use ful in increasing cerebral blood flow after head trauma (Cherian et aI., 1999) , but not surprisingly, did not de crease damage in models associated with significant en dothelial disruption such as ischemia (Prado et aI., 1996) and subarachnoid hemorrhage (Pluta et aI., 2000) . Because L-arginine and simvastatin increase rCBF, they may also be useful for enhancing the delivery of other coadministered drugs to the hypoperfused brain. Therefore, strategies targeting vascular eNOS activity and generating nitric oxide within vascular compart ments provide useful approaches to treat CNS disorders characterized by low flow states (Scandinavian Simvas tatin Survival Study Group, 1994; Byington et aI., 1995; Sacks et aI., 1996; Blauw et aI., 1997; Delanty and Vaughan, 1997) .
